HIV的標準護理是需要每日口服的三種藥物組合，但口服多種藥物會引發順應性問題。強生與葛蘭素史克的子公司ViiV的HIV注射劑被證實提供不低於口服藥物的療效，安全性與耐受性。
ViiV Healthcare presented data from its ATLAS and FLAIR Phase III trials of its two-drug combo HIV treatment that is injected once a month. The combination was found to be non-inferior to a standard of care, daily oral three-drug combination.
葛蘭素史克子公司ViiV Healthcare 提供了其 ATLAS 和 FLAIR 三期臨床試驗的數據，這兩種藥物組合 HIV 治療每月注射一次。該組合被發現不低於標準的護理，每日口服三藥組合。
ViiV’s two-drug combo is a combination of its cabotegravir and Janssen, a Johnson & Johnson company’s, Edurant (rilpivirine). The combo is injected every four weeks. The data was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington.
ViiV 的兩種藥物組合是它的卡博格韋和楊森（Janssen）的組合，後者是強生公司的 Edurant （利吡韋林）。梳子每四周注射一次。這些數據是在2019年華盛頓西雅圖的逆轉錄病毒和機會感染會議上公佈的。
“With FLAIR and ATLAS, we now have positive results from two pivotal Phase III studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily, oral three-drug regimen for the treatment of HIV,” stated John C. Pottage, Jr., ViiV’s chief scientific and medical officer. “We are also encouraged by patient preference data showing that nearly all participants who switched to the long-acting injectable regimen preferred it over their prior oral therapy.”
ViiV 首席科學和醫療官員約翰· C ·波蒂奇( John C . Pottage )說：“通過 FLAIR 和 ATLAS，我們現在從兩項關鍵的 III 期研究中得到了積極的結果，證明這種長效的、每月一次的注射方案與每天口服的三種藥物治療 HIV 的養生法具有相似的療效、安全性和耐受性。”“我們也對患者的偏好數據感到鼓舞，這些數據顯示，幾乎所有轉向長效注射養生法的參與者都更喜歡這種方法，而不是之前的口服治療。”
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.
通常情況下，病人更喜歡口服藥物而不是注射或輸液，但每日的藥丸有時會導致順應性問題。在這種聯合注射的情況下，如果獲得批准，需要病人每月去診所或醫生看一次注射。
ATLAS, which stands for Antiretroviral Therapy as Long-Acting Suppression, had a primary endpoint of showing non-inferiority to an oral three-drug dose of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent. The endpoint was met, with virologic suppression rates at Week 48 similar in both treatment arms.
ATLAS 是抗逆轉錄病毒治療的長期抑制，它的主要終點是顯示出與口服三種藥物劑量的兩種核苷逆轉錄酶抑制劑（ NRTIs ）和第三種藥物的非劣效性。在48周時，兩個治療臂的病毒學抑制率相似。
閱讀更多 匯眾醫療 的文章
